PwC Survey Finds Dissatisfaction Among Drug, Device Makers About FDA's Personalized Rx Efforts

The survey revealed that only 8 percent of drug and device makers feel the FDA "is doing enough to advance personalized medicine." Moreover, 56 percent of respondents familiar with FDA's Critical Path Initiative said that the agency "lacks the capability to implement the initiative," which aims to bring innovative drugs to market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.